HRAS and thyroid cancer: Tipifarnib has also recently been designated as a breakthrough therapy by the FDA for HRas mutant head and neck squamous cell carcinoma after positive results from a phase II clinical trial and has shown preclinical activity in HRas mutant thyroid cancer cell lines [286,287].